Breadcrumb

Haneen Shalabi, D.O.

Haneen Shalabi, D.O.

  • Center for Cancer Research
  • National Cancer Institute
Pediatric Oncology Branch

RESEARCH SUMMARY

Dr. Shalabi's primary research interests are novel immunotherapy targets for chemo-resistant acute lymphoblastic leukemia. Her clinical focus is the treatment of relapsed/refractory pediatric patients with hematologic malignancies utilizing chimeric antigen receptor (CAR) T cell therapies. Additional areas of interest include neurocognitive effects of immunotherapy in pediatric patients and bone marrow  transplantation for patients with malignant and non-malignant diseases.

Areas of Expertise

1) pediatric leukemia 2) chimeric antigen receptor (CAR) T cell therapy for pediatric leukemia 3) immunotherapy for relapsed/refractory hematologic malignancies 4) cognitive effects post-immunotherapy

Information for Patients

Learn more about the Leukemia, Lymphoma, Transplant and Cell Therapy Team and clinical trials.

Clinical Trials

Publications

Selected Key Publications

Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy

Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Streumph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN.
Journal of Immunotherapy. 41: 350-358, 2018. [ Journal Article ]

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, Lee DW, Shern JF, Fry TJ, Shah NN.
Hematologica. 103: e215-e218, 2018. [ Journal Article ]

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia

Shalabi H, Angiolillo A, Fry TJ.
Frontiers in Pediatrics. 3: 1-12, 2015. [ Journal Article ]

Cell-based Therapies: A New Frontier of Personalized Medicine

Shalabi H, Khuu H, Fry TJ, Shah NN.
2018. [ Book Chapter ]

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.
Nature Medicine. 24: 20-28, 2018. [ Journal Article ]